Gunderson Dettmer represented client RIGImmune, a biopharmaceutical company developing a new class of RNA immunotherapeutics, in its acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by RNA viruses. The newly combined company will work to further advance novel compounds that both activate the natural immune activation and demonstrate antiviral activity.

In the announcement of the acquisition, President of RIGImmune Susan Sobolov said, “Joining with the experienced Subintro team will allow us to further advance our development of new treatments, prophylactics and vaccine adjuvants for respiratory diseases caused by RNA viruses. By combining our stem-loop RNA therapeutics or “SLRs” with the Subintro antivirals and novel topical delivery systems, we aim to achieve optimal management of viral respiratory diseases.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Tim Kulis and Annie Cho.

Companies
RIGImmune